The addition of rituximab reduces the incidence of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma

British Journal of Haematology

Volumn 157, Issue 3, 2012, Pages 401-403

  Mitrovic, Zdravko ^a,b   Bast, Martin ^a   Bierman, Philip J ^a   Bociek, Robert G ^a   Vose, Julie M ^a   Chan, Wing C ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Diffuse large B cell lymphoma; Non Hodgkin lymphoma; Relapse; Rituximab; Secondary central nervous system lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LETTER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; DRUG EVALUATION; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859490234     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08998.x     Document Type: Letter

References (8)

1. Bernstein, S.H., Unger, J.M., Leblanc, M., Friedberg, J., Miller, T.P. & Fisher, R.I. (2009) Natural history of CNS relapse in patients with aggressive non-Hodgkin lymphoma: a 20-year follow up analysis of SWOG 8516-The Southwest Oncology Group. Journal of Clinical Oncology, 27, 114-119.
2. Boehme, V., Schmitz, N., Zeynalova, S., Loeffler, M. & Pfreundschuh, M. (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood, 113, 3896-3901.
3. Feugier, P., Virion, J.M., Tilly, H., Haioun, C., Marit, G., Macro, M., Bordessoule, D., Recher, C., Blanc, M., Molina, T., Lederlin, P. & Coiffier, B. (2004) Incidence and risk factors for central nervoussystem occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology, 15, 129-133.
4. Shimazu, T., Notohara, K. & Ueda, Y. (2009) Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single centre experience. International Journal of Hematology, 89, 577-583.
5. Tai, W.M., Chung, J., Tang, P.L., Koo, Y.X., Hou, X., Tay, K.W., Quek, R., Tao, M. & Lim, S.T. (2011) Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Annals of Hematology, 90, 809-818.
6. Tomita, N., Yokoyama, M., Yamamoto, W., Watanabe, R., Shimazu, Y., Masaki, Y., Tsunoda, S., Hashimoto, C., Murayama, K., Yano, T., Okamoto, R., Kikuchi, A., Tamura, K., Sato, K., Sunami, K., Shibayama, H., Takimoto, R., Ohshima, R., Hatta, Y., Moriuchi, Y., Kinoshita, T., Yamamoto, M., Numata, A., Ishigatsubo, Y. & Takeuchi, K. (2011) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Science, doi:
7. Villa, D., Connors, J.M., Shenkier, T.N., Gascoyne, R.D., Sehn, L.H. & Savage, K.J. (2010) Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Annals of Oncology, 21, 1046-1052.
8. Yamamoto, W., Tomita, N., Watanabe, R., Yukako, H., Nakajima, Y., Hyo, R., Hashimoto, C., Motomura, S. & Ishigatsubo, Y. (2010) Central nervous system involvement in diffuse large B-cell lymphoma. European Journal of Hematology, 85, 6-10.